NPS Pharmaceuticals Q3 net loss decreases

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company, has reported that net loss for the third quarter ended September 30, 2012 was $3.32 million, or $0.04 loss per share, compared to net loss of $12.35 million, or $0.14 loss per share, for the same quarter ended September 30, 2011.

Total revenues for the third quarter ended September 30, 2012 were $27.02 million, compared to $24.6 million for the same quarter ended September 30, 2011.

Net loss for the nine months ended September 30, 2012 was $6.53 million, or $0.08 loss per share, compared to net loss of $27.63 million, or $0.35 loss per share, for the same period ended September 30, 2011.

Total revenues for the nine months ended September 30, 2012 were $103.46 million, compared to $75.39 million for the same period ended September 30, 2011.

Francois Nader, president and CEO, NPS Pharmaceuticals, said: "We continue to make strong progress towards completing our Biologic License Application for Natpara as the first replacement therapy for hypoparathyroidism. We remain on track to deliver a submission in line with our mid-2013 guidance."